Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
NEWRON PHARMACEUT. EO-20
NP5Current price
8.34 EUR
-0.14 EUR (-1.65%)
Last closed
8.25 EUR
Company
–
ISIN
IT0004147952
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
172 562 927 EUR
Yield for 12 month
+51.45 %
1Y
3Y
5Y
10Y
15Y
NP5
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy. Address: Via Antonio Meucci 3, Bresso, MI, Italy, 20091
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
–P/E ratio
–Dividend Yield
–Current Year
+9 560 992 EUR
Last Year
+6 153 226 EUR
Current Quarter
+3 440 112 EUR
Last Quarter
+3 597 628 EUR
Current Year
+9 348 807 EUR
Last Year
+6 153 226 EUR
Current Quarter
+3 343 320 EUR
Last Quarter
+3 487 839 EUR
Key Figures NP5
1 year
3 years
5 years
10 years
EBITDA
-15 019 567 EUR
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-33.24 %
PEG Ratio
–
Return On Equity TTM
-14642.56 %
Wall Street Target Price
–
Revenue TTM
7 037 740 EUR
Book Value
-1.63 EUR
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-38 %
Dividend Yield
–
Gross Profit TTM
6 153 226 EUR
Earnings per share
-1.04 EUR
Diluted Eps TTM
-1.04 EUR
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-270.17 %
Dividend Analytics NP5
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History NP5
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation NP5
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
12.5471
Enterprise Value Revenue
29.3304
Price Sales TTM
24.5197
Enterprise Value EBITDA
-15.435
Price Book MRQ
7.6103
Financials NP5
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators NP5
For 52 weeks
4.3 EUR
12.12 EUR
50 Day MA
8.65 EUR
Shares Short Prior Month
–
200 Day MA
8.82 EUR
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart